OptimizeRx Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de OptimizeRx de 29.1% y 19.4% respectivamente, mientras que el BPA crecerá en un 32.2% al año.

Información clave

29.1%

Tasa de crecimiento de los beneficios

32.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services	30.9%
Tasa de crecimiento de los ingresos	19.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	10 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24

Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

May 10

Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Mar 29

Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)

Feb 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:OPRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	114	-11	N/A	N/A	7
12/31/2024	101	-12	N/A	N/A	7
6/30/2024	83	-18	-2	-2	N/A
3/31/2024	78	-18	-6	-5	N/A
12/31/2023	72	-18	-8	-7	N/A
9/30/2023	63	-14	0	2	N/A
6/30/2023	62	-14	2	4	N/A
3/31/2023	62	-14	6	6	N/A
12/31/2022	62	-11	10	11	N/A
9/30/2022	63	-10	6	7	N/A
6/30/2022	64	-7	3	3	N/A
3/31/2022	64	-3	3	3	N/A
12/31/2021	61	0	0	1	N/A
9/30/2021	57	1	-1	-1	N/A
6/30/2021	52	1	-1	-1	N/A
3/31/2021	47	-1	-1	-1	N/A
12/31/2020	43	-2	-6	-6	N/A
9/30/2020	34	-6	-6	-5	N/A
6/30/2020	29	-7	-7	-6	N/A
3/31/2020	27	-5	-8	-6	N/A
12/31/2019	25	-3	-3	-2	N/A
9/30/2019	24	-1	0	1	N/A
6/30/2019	24	1	2	3	N/A
3/31/2019	22	0	2	2	N/A
12/31/2018	21	0	1	1	N/A
9/30/2018	19	0	0	0	N/A
6/30/2018	16	-1	-2	-2	N/A
3/31/2018	14	-1	N/A	-2	N/A
12/31/2017	12	-2	N/A	-1	N/A
9/30/2017	10	-2	N/A	-2	N/A
6/30/2017	9	-2	N/A	-1	N/A
3/31/2017	8	-2	N/A	0	N/A
12/31/2016	8	-2	N/A	0	N/A
9/30/2016	7	-2	N/A	0	N/A
6/30/2016	8	-1	N/A	0	N/A
3/31/2016	7	-1	N/A	0	N/A
12/31/2015	7	-1	N/A	1	N/A
9/30/2015	7	0	N/A	1	N/A
6/30/2015	7	0	N/A	0	N/A
3/31/2015	7	0	N/A	0	N/A
12/31/2014	7	-1	N/A	0	N/A
9/30/2014	6	-1	N/A	1	N/A
6/30/2014	6	-1	N/A	1	N/A
3/31/2014	5	-1	N/A	1	N/A
12/31/2013	5	0	N/A	1	N/A
9/30/2013	4	0	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que OPRX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que OPRX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que OPRX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (19.4% al año) de OPRX crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 19.4% al año) de OPRX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OPRX se prevé que sea elevada dentro de 3 años.

OptimizeRx Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$0.66 loss

OptimizeRx Corporation Reiterates Financial Guidance for the Full Year 2024

Price target increased by 7.5% to US$16.40

OptimizeRx Corporation Revises Earnings Guidance for the Year 2023

Consensus revenue estimates increase by 11%, EPS downgraded

OptimizeRx Corporation Increases Earnings Guidance for the Year 2023

Recent updates

OptimizeRx Corporation announced delayed 10-Q filing

Consensus EPS estimates upgraded to US$0.66 loss

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

OptimizeRx Corporation, Annual General Meeting, Jun 05, 2024

OptimizeRx Corporation to Report Q1, 2024 Results on May 14, 2024

OptimizeRx Corporation Reiterates Financial Guidance for the Full Year 2024

OptimizeRx Corporation announced delayed annual 10-K filing

OptimizeRx Corporation Announces Changes to its Board

Insider recently sold US$61k worth of stock

Insider notifies of intention to sell stock

Price target increased by 7.5% to US$16.40

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

OptimizeRx Corporation Revises Earnings Guidance for the Year 2023

Consensus revenue estimates increase by 11%, EPS downgraded

New minor risk - Shareholder dilution

OptimizeRx Corporation Increases Earnings Guidance for the Year 2023

OptimizeRx Corporation Provides Earnings Guidance for the Year 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OptimizeRx Corporation to Report Q3, 2023 Results on Nov 06, 2023

Optimizerx Corporation to Change the Designation of Stephen L. Silvestro from Chief Commercial Officer to President

OptimizeRx Corporation (NasdaqCM:OPRX) signed an agreement to acquire Healthy Offers, Inc. for $95 million.

OptimizeRx Corp. Unveils a Significant Enhancement to its Omni-Channel Healthcare Engagement Platform

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 13%

New minor risk - Share price stability

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

OptimizeRx Corporation to Report Q2, 2023 Results on Aug 14, 2023

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

Now 22% undervalued after recent price drop

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

OptimizeRx Corporation Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$27.33

Third quarter 2022 earnings: EPS exceeds analyst expectations

OptimizeRx Corporation Reiterates Earnings Guidance for the Year 2022

OptimizeRx Corporation to Report Q3, 2022 Results on Nov 08, 2022

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Chief Commercial Officer recently bought US$50k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

OptimizeRx Corporation Provides Financial Guidance for the Year 2022

OptimizeRx extends reach with Cooler Screens Partnership

OptimizeRx Corporation to Report Q2, 2022 Results on Aug 09, 2022

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

OptimizeRx Corporation Completes Platform Integration of TelaRep One-Click Prescriber Connectivity Solution

OptimizeRx Corporation (NasdaqCM:OPRX) announces an Equity Buyback for $20 million worth of its shares.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OptimizeRx Corporation Reaffirms Financial Guidance for the Year 2022

Consensus forecasts updated

Price target decreased to US$89.75

OptimizeRx Corporation, Annual General Meeting, Jun 09, 2022

OptimizeRx Corporation to Report Q1, 2022 Results on May 04, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Consensus forecasts updated

OptimizeRx Corporation Announces Earnings Guidance for the Full Year 2022

OptimizeRx Corporation to Report Q4, 2021 Results on Feb 24, 2022

Insider notifies of intention to sell stock

Consensus forecasts updated

CEO & Director notifies of intention to sell stock

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Third quarter 2021 earnings released: EPS US$0.002 (vs US$0.019 loss in 3Q 2020)